Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5 -trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-yla mino)-benzamide

Details for Australian Patent Application No. 2006276205 (hide)

Owner Novartis AG

Inventors Sutton, Paul Allen; Karpinski, Piotr H.; Brozio, Jorg; Manley, Paul W.; Monnier, Stephanie; Shieh, Wen-Chung; Wu, Raeann

Agent Davies Collison Cave

Pub. Number AU-B-2006276205

PCT Pub. Number WO2007/015871

Priority 60/701,406 20.07.05 US; 60/716,213 12.09.05 US

Filing date 18 July 2006

Wipo publication date 8 February 2007

Acceptance publication date 19 August 2010

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

14 February 2008 PCT application entered the National Phase

  PCT publication WO2007/015871 Priority application(s): WO2007/015871

19 August 2010 Application Accepted

  Published as AU-B-2006276205

16 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006276207-Electrical connector configured as a fastening element

2006276204-Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)- 5-trifluoromethyl-phenyl]-3-(4-pyridin-3yl-pyrimidin-2-ylamino)-benzamide